CD4 and neoplasm: Altogether, we demonstrated that DNA-immunization with drug resistant INs can confer resistance to establishment of tumors expressing homologous IN variants which does not rely on 100% identity between the immunogen and antigen present in the challenge, but rather on the profile of immune response against IN as tumor associated antigen, with dominance of the specific multicytokine expressing CD4+ and CD8+ T cells.